Article
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.
Proceedings of the National Academy of Sciences of the United States of America - 20 Jun 2000
Sampson J H, Crotty L E, Lee S, Archer G E, Ashley D M, Wikstrand C J, Hale L P, Small C, Dranoff G, Friedman A H, Friedman H S, Bigner D D
Abstract excerpt
The epidermal growth factor receptor (EGFR) is often amplified and rearranged structurally in tumors of the brain, breast, lung, and ovary. The most common mutation, EGFRvIII, is characterized by an in-frame deletion of 801 base pairs, resulting in the generation of a novel tumor-specific epitope at the fusion junction. A murine homologue of the human EGFRvIII mutation was created, and an IgG2a murine mAb, Y10,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.